A post hoc analysis found similar safety outcomes for fixed-duration regimens containing acalabrutinib/venetoclax across age groups in treatment-naive CLL.
|Videos|May 5, 2011
Dr. Cobb on the Complications of Reimbursement in Oncology
Author(s)Patrick W. Cobb, MD
Dr. Patrick Cobb from the Community Oncology Alliance on the Complications of Reimbursement in Oncology
Advertisement
Patrick W. Cobb, MD, FACP, the President, Community Oncology Alliance (COA) on the Complications of Reimbursement in Oncology
Advertisement
Related to this article
Mayo Clinic researchers identified a protein that cancer cells use to shut down the body's immune response, which may help develop novel cancer treatments.
T-DXd plus pertuzumab was approved in China as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
Topline phase 2a data showed a 48.9% six-month progression-free survival rate with intranasal NEO100 in previously treated IDH1-mutant glioma.
Komal Jhaveri, MD, FACP, discusses the role of CDK4/6 inhibitors for patients with hormone receptor–positive disease and how oral SERD use is changing.
Jorge Cortes, MD, discusses the FDA approval of orally disintegrating nilotinib tablets for patients with chronic myeloid leukemia.
PDS Biotechnology will prioritize the IL-12 immunocytokine PDS0301 in metastatic colorectal cancer and pursue a partnership strategy for PDS0101.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
Advertisement
Advertisement
Trending on OncLive
1
T-DXd Plus Pertuzumab Is Approved in China for First-Line HER2+ Metastatic Breast Cancer
2
Intranasal NEO100 Meets Primary End Point in Recurrent IDH1-Mutant High-Grade Glioma
3
Phase 3 VERSATILE-003 Trial of PDS0101 in HNSCC Is Discontinued
4
What Does the FDA Approval of Orally Disintegrating Nilotinib Tablets Mean for CML Practice?
5